Aemetis (NASDAQ:AMTX) Stock Price Breaks Below 200-Day Moving Average - What's Next?

Key Points

• Aemetis shares fell below their 200-day moving average, trading as low as $1.55 and last changing hands at $1.56, down 2.5%. The stock’s market capitalization is approximately $112.6 million.
• Analysts’ consensus rating is “Hold”, with one Buy and one Sell rating and an average price target of $11.88. Recent ratings included a reaffirmed Sell from Weiss Ratings and an upgrade to Hold from Wall Street Zen.
• Aemetis reported a quarterly loss of $0.13 per share, beating estimates for a $0.29 loss, though revenue of $62.7 million fell short of expectations. Institutional investors own approximately 27.02% of the company.

Aemetis, Inc (NASDAQ:AMTX - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $2.09 and traded as low as $1.55. Aemetis shares last traded at $1.56, with a volume of 456,981 shares.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AMTX shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Aemetis in a report on Friday, July 17th. Wall Street Zen upgraded Aemetis from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $11.88.

Aemetis Trading Down 2.5%

The firm has a market capitalization of $112.59 million, a PE ratio of -1.71 and a beta of 1.82. The business's 50 day simple moving average is $1.83 and its 200 day simple moving average is $2.09.

Aemetis (NASDAQ:AMTX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The specialty chemicals company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.16. The company had revenue of $62.70 million for the quarter, compared to analysts' expectations of $67.69 million. Analysts forecast that Aemetis, Inc will post -0.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in shares of Aemetis in the 2nd quarter valued at about $283,000. Bank of America Corp DE increased its position in Aemetis by 148.3% during the 1st quarter. Bank of America Corp DE now owns 101,486 shares of the specialty chemicals company's stock valued at $324,000 after buying an additional 60,611 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Aemetis by 10,632.5% during the first quarter. Royal Bank of Canada now owns 8,908 shares of the specialty chemicals company's stock valued at $28,000 after acquiring an additional 8,825 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Aemetis in the 1st quarter valued at approximately $272,000. Finally, Sanctuary Advisors LLC purchased a new stake in Aemetis during the 1st quarter worth approximately $33,000. 27.02% of the stock is currently owned by institutional investors.

About Aemetis

Aemetis, Inc is a renewable fuels and renewable chemicals company focused on developing and operating low-carbon production facilities. Its activities include the production of renewable natural gas, renewable fuels, ethanol, and other products designed to reduce greenhouse gas emissions from transportation and industrial operations.

The company operates an ethanol production facility in California's Central Valley and develops dairy-based biogas and renewable natural gas projects that capture methane from agricultural waste.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.